|
|
|
|
|
|
|
14.05.26 - 16:51
|
ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31st, 2026 (GlobeNewswire EN)
|
|
|
MADRID and CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a global leader in epigenetics, today reported financial results for the three months ended March 31, 2026, and provided a corporate update on recent developments....
|
|
|
|
|
|
|
13.05.26 - 14:03
|
ORYZON to Present Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia at EHA 2026 (GlobeNewswire EN)
|
|
|
MADRID and CAMBRIDGE, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a global leader in epigenetics, today announced that updated positive clinical data from two Phase Ib clinical trials evaluating its selective LSD1 inhibitor iadademstat in acute myeloid leukemia (AML) will be presented in two poster sessions at the European Hematology Association (EHA) Annual Congress, taking place June 11-14, 2026 in Stockholm, Sweden.“We are encouraged by the updated findings from both the ALICE-2 and FRIDA trials, which continue to support the clinical activity and favorable safety profile of iadademstat-based combinations in AML,” said Carlos Buesa, Chief Executive Officer of Oryzon. “We look forward to presenting updated data at EHA 2026 from a larger patient cohort in the ALICE-2 study, likely representing approximately 75–80% of the planned enrollment, which we believe will provide a more mature assessment of b...
|
|
|
|
|
|
|
|
|
11.05.26 - 07:21
|
Almirall Continues Its Positive Trajectory in Q1 2026 in Line With Expectations – Led by 19.3% YoY Growth of Its European Dermatology Business (Business Wire)
|
|
|
Almirall's European Dermatology business delivered solid growth of 19.3% YoY, reaching €166.3 MM in Q1 2026, driven by strong momentum across key growth drivers. This contributed to overall Net Sales of €291 MM, up 2.2% YoY and reflecting 9% growth on a Last-Twelve-Months (LTM) basis.
Performance continues to be driven by the biologics portfolio, with Ilumetri® showing 11.8% increase in sales vs Q1 2025 (total of €61.6 MM), and Ebglyss® delivering €41.9 MM quarterly sales – more than 2x YoY – boosted by sustained growth in recent launch countries.
Strong performance of the broad dermatology product portfolio in line with expectations – products driving relevance of Almirall in medical dermatology, including Wynzora® (20.8%, total of €9.3 MM) and Klisyri® (7.2%, total of €7.4 MM).
Total EBITDA was €67.5 MM, corresponding to 23.2% over Net Sales – improvement versus FY 2025 (21%).
Continued R&D pipeline progress includes the start of phase I of anti-IL-13/OX40L bispecific antibody...
|
|
|
|
|
07.05.26 - 19:24
|
Grifols Q1 Profit Rises (AFX)
|
|
|
MADRID (dpa-AFX) - Plasma-derived medicines company Grifols S.A. (GRFS) on Thursday reported higher first-quarter profit and revenue, driven by continued strong demand for immunoglobulin therapies......
|
|
|
|
|
|
|
04.05.26 - 09:45
|
Evotec: Schneller als gedacht – Aktie zieht deutlich an (Der Aktionaer)
|
|
|
Evotec meldet Fortschritte in der Dermatologie-Partnerschaft mit Almirall. Aus der gemeinsamen, auf mehrere Zielstrukturen ausgerichteten Wirkstoffsuche wurde ein präklinischer Entwicklungskandidat ausgewählt. Ziel sind neue Therapieoptionen für immunvermittelte entzündliche Hauterkrankungen mit hohem medizinischem Bedarf....
|
|
|
|
|
|
|
04.05.26 - 07:33
|
Corporate News: Evotec SE (EQS)
|
|
|
Evotec gibt ersten präklinischen Entwicklungskandidaten aus Dermatologie-Kooperation mit Almirall bekannt...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
